Nazartinib

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameNazartinib
Drug Alias Name那扎替尼纳扎替尼EGF-816EGFRmut-TKI EGF816
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR T790M inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1EGFR T790M
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungBronchial NeoplasmsLung Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[17] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma AgUniversity Of Cologne
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungBronchial Neoplasms
Inactive IndicationsLung NeoplasmsColorectal NeoplasmsTriple Negative Breast Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A